MedTrace Logo

Imatinib Mesylate in Treating Patients With Gliomas

NCT00039364 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2012-07-24

No results posted yet for this study

Summary

RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and slow the growth of the tumor.

PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have gliomas.

Conditions

Interventions

DRUG

imatinib mesylate

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • Eric Raymond, MD, PhD · Gustave Roussy, Cancer Campus, Grand Paris

  • Martin J. van Den Bent, MD · Daniel Den Hoed Cancer Center at Erasmus Medical Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-03-31
Primary Completion
2004-08-31

Countries

  • Austria
  • Belgium
  • France
  • Italy
  • Netherlands
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00039364 on ClinicalTrials.gov